Exchange: NASDAQ·Updated 07:03 PM EDT

TLSI News

News
all
press releases
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.read more...
Benzinga
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.read more...
Benzinga
More News
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.read more...
Benzinga
TriSalus Lands Key FDA Clearance as PEDD Platform Pushes into Tougher Anatomy
TriSalus Life Sciences (NASDAQ:TLSI) cleared a regulatory hurdle that could materially broaden the reach of its Pressure-Enabled Drug Delivery platform.
24-7 Market News
TriSalus Life Sciences Receives FDA Clearance for TriNav Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery (PEDD) Portfolio for Liver Embolization
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug...
Business Wire
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...
Business Wire
TriSalus Life Sciences Q2 Earnings Call Highlights
TriSalus Life Sciences Q2 Earnings Call Highlights...
Yahoo! Finance: News
TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter...
Business Wire
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences Inc. (Nasdaq: TLSI) (TriSalus or the Company), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David...
Business Wire
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and...
Business Wire
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks

Advertisement|Remove ads.